Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes

Component: Nanoparticle Core; Description: Gelatin type A (porcine skin, 175 bloom) — biodegradable protein-based polymer; prepared by two-step desolvation process

Component: Nanoparticle Size; Description: ~211 nm (monodisperse)

Component: Surface Modification; Description: Introduction of sulfhydryl groups via 2-iminothiolane (Traut's reagent)

Component: Adapter Protein; Description: NeutrAvidin™ (NAv) — avidin derivative with high biotin affinity (KD = 10⁻¹⁵ M); conjugated via sulfo-MBS crosslinker to sulfhydryl groups; FITC-labeled for tracking

Component: NAv Binding Capacity; Description: 7.36 × 10⁻¹⁰ mol NAv per mg nanoparticles

Component: Targeting Antibody; Description: Biotinylated mouse anti-human CD3 antibody (Cymbus Biotechnology)

Component: Control Nanoparticles; Description: IgG isotype-conjugated nanoparticles (IgG-NP)

Component: Coupling Strategy; Description: Avidin-biotin complex formation; biotinylated antibodies bind to NAv on particle surface

Component: Cell Types; Description: • Jurkat (T-cell leukemia, CD3⁺ 98.2%)<br>• CEM (T-cell leukemia, CD3⁺ 37.5%)<br>• Primary T lymphocytes (PBL, CD3⁺ 82%)<br>• MCF-7 (breast cancer, CD3⁻ negative control)

Parameter: Nanoparticle Preparation; Details: Two-step desolvation: gelatin dissolved in water (50°C); acetone added; pH adjusted to 2.5; glutaraldehyde crosslinking; purified by centrifugation

Parameter: Antibody Conjugation; Details: NAv activated with sulfo-MBS; conjugated to thiolated nanoparticles (12 h, 20°C); biotinylated anti-CD3 (25 μg/mL) added to NAv-NPs (90 min, 10°C)

Parameter: Antibody Quantification; Details: Western blot (semi-quantitative); anti-mouse IgG-AP secondary; BCIP/NBT substrate; standard calibration curve

Parameter: CD3 Expression; Details: Flow cytometry: PE-conjugated anti-CD3 or IgG control; 10,000 cells/sample; FACSCalibur; CellQuestPro

Parameter: Cellular Uptake Assays; Details: 1×10⁶ cells/mL; 1 mg/mL nanoparticles; 4 h incubation at 37°C or 4°C; flow cytometry (FITC channel) and CLSM

Parameter: Competition Experiments; Details: Free anti-CD3 antibody (2.5 μg) added 30 min prior to nanoparticle incubation

Parameter: Endocytosis Inhibition; Details: Cytochalasin (1 μg/mL) added 30 min prior to nanoparticle incubation; temperature shift to 4°C

Parameter: Confocal Microscopy; Details: Leica DM IRBE; sequential scanning; cell membranes stained with concanavalin A-Alexa Fluor 594; inner sections imaged

Parameter: Controls; Details: IgG-NP (isotype control); CD3⁻ MCF-7 cells; free anti-CD3 competition; inhibition at 4°C

Analysis Category: Nanoparticle Characterization; Methods: Photon correlation spectroscopy (size); microelectrophoresis (zeta potential); spectrophotometry (sulfhydryl groups, 412 nm, DTNB); gravimetric analysis (protein content)

Analysis Category: Antibody Binding; Methods: Western blot (SDS-PAGE, nitrocellulose transfer, anti-mouse IgG-AP, BCIP/NBT); densitometry vs. standard curve

Analysis Category: CD3 Expression; Methods: Flow cytometry (FACSCalibur): PE-anti-CD3; FL-2 channel; % positive cells; mean fluorescence intensity

Analysis Category: Cellular Uptake Quantification; Methods: Flow cytometry: FITC fluorescence (FL-1, 530 nm); 10,000 cells/sample; % positive cells and MFI

Analysis Category: Cellular Localization; Methods: CLSM (Leica DM IRBE); sequential scanning; Alexa Fluor 594-concanavalin A (membrane); FITC-NPs; LCS software for image processing

Analysis Category: Endocytosis Mechanism; Methods: Temperature shift (4°C vs. 37°C); cytochalasin inhibition (1 μg/mL)

Parameter: Nanoparticle size; Value: ~211 nm

Parameter: NAv binding capacity; Value: 7.36 × 10⁻¹⁰ mol NAv/mg NPs

Parameter: Anti-CD3 binding; Value: Quantitative (complete binding to NAv-NPs; no binding to unmodified/thiolated NPs)

Parameter: Antibody coupling strategy; Value: Avidin-biotin complex formation (efficient and specific)

Cell Type: Jurkat; % CD3-Positive: 98.2%

Cell Type: CEM; % CD3-Positive: 37.5%

Cell Type: Primary T lymphocytes (PBL); % CD3-Positive: 82%

Cell Type: MCF-7 (breast cancer); % CD3-Positive: Not detectable

Cell Type: Jurkat; % Uptake (αCD3-NP): 83.7 ± 15.0%; MFI (αCD3-NP): 131.2 ± 17.1; % Uptake (IgG-NP): 5.1 ± 2.8; MFI (IgG-NP): 8.9 ± 2.7

Cell Type: CEM; % Uptake (αCD3-NP): 29.4 ± 14.3%; MFI (αCD3-NP): 52.7 ± 12.8; % Uptake (IgG-NP): 6.2 ± 1.7; MFI (IgG-NP): 7.3 ± 1.2

Cell Type: MCF-7 (CD3⁻); % Uptake (αCD3-NP): 6.7 ± 2.3%; MFI (αCD3-NP): 10.8 ± 3.8; % Uptake (IgG-NP): 5.3 ± 1.9; MFI (IgG-NP): 11.3 ± 1.9

Cell Type: Correlation; % Uptake (αCD3-NP): Uptake correlates with CD3 expression level; MFI (αCD3-NP): -; % Uptake (IgG-NP): -; MFI (IgG-NP): -

Treatment: αCD3-NP alone; Jurkat (MFI): 131.2 ± 17.1; CEM (MFI): 52.7 ± 12.8

Treatment: αCD3-NP + free anti-CD3; Jurkat (MFI): 42.1 ± 12.3 (≥3× reduction); CEM (MFI): 12.5 ± 3.7 (≥3× reduction)

Treatment: αCD3-NP + IgG control; Jurkat (MFI): 81.7 ± 24.8; CEM (MFI): 28.3 ± 8.7

Treatment: Specificity; Jurkat (MFI): Free anti-CD3 blocks uptake; IgG control has minimal effect; CEM (MFI): -

Condition: 37°C + αCD3-NP; Uptake: Pronounced intracellular distribution; Interpretation: Active uptake

Condition: 4°C + αCD3-NP; Uptake: Substantially inhibited; Interpretation: Energy-dependent process

Condition: 37°C + cytochalasin; Uptake: Clearly impeded; Interpretation: Actin-dependent (endocytosis)

Condition: 37°C + IgG-NP; Uptake: No uptake; Interpretation: Receptor-specific

Condition: Mechanism; Uptake: Receptor-mediated endocytosis; Interpretation: -

1. No drug loading demonstrated: The study focuses on targeting and uptake of empty nanoparticles; therapeutic efficacy with drug-loaded particles was not demonstrated.

2. In vitro only: All experiments were performed in cultured cell lines and primary cells; no in vivo targeting, biodistribution, or therapeutic studies.

3. Modest uptake in CEM cells: Only 29.4% uptake in CEM cells (vs. 83.7% in Jurkat), likely due to lower CD3 expression; this suggests the approach may be less effective for cells with lower receptor density.

4. Primary T cell activation required: Primary T lymphocytes were stimulated with PHA and IL-2, which may alter CD3 expression and endocytic activity compared to resting T cells.

5. Gelatin nanoparticle stability: Gelatin nanoparticles are biodegradable but may have limited stability in physiological conditions; controlled release properties were not characterized in this study.

6. Avidin-biotin system immunogenicity: NeutrAvidin is a bacterial protein that could elicit immune responses upon repeated administration; not addressed.

7. No comparison to other delivery systems: The study does not benchmark nanoparticle uptake against other targeted delivery approaches (e.g., immunoliposomes, antibody-drug conjugates).

8. No quantification of internalized particle number: Flow cytometry measures fluorescence intensity but does not distinguish between surface-bound and internalized particles; confocal microscopy confirmed internalization but was not quantified.

9. Potential for nanoparticle degradation in endosomes: The study does not assess the fate of nanoparticles after internalization (e.g., degradation, drug release, exocytosis).

10. Single targeting ligand: Only anti-CD3 antibody was tested; the platform's ability to target other cell types with other antibodies was not demonstrated.

11. No assessment of functional effects: The study does not evaluate whether nanoparticle binding affects T cell function, proliferation, or activation.

12. Confocal microscopy image quality: The study notes that "pictures were taken within inner sections of the cells," but the resolution and colocalization analysis are limited by the microscopy techniques available at the time.

Report prepared based on the published Biomaterials article. For full experimental details and complete references, please refer to the original publication.